CrystalGenomics

We strive to be a global biopharma leader whose mission is

to develop innovative, life-changing medicine

Company History

CrystalGenomics history

Key events marking CrystalGenomics' growth and evolution.

Present - 2011’s
2021
  • 01

    Received orphan drug designation from the U.S. FDA for targeted anticancer drug, ivaltinostat, to treat acute myeloid leukemia (AML)

2020
  • 12

    Applied for regulatory approval of Acelex, next-gen anti-inflammatory drug, in Brazil

  • 12

    Reported completion of Phase 1 SAD study for CG-750

  • 12

    Completed Phase 1 study for polmacoxib + pregabalin FDC

  • 11

    Selected by Korea's Financial Services Commission as one of the top 1000 innovative firms to support

  • 10

    Received designation for expedited approval of ivaltinostat by Korea's Ministry of Food and Drug Safety

  • 08

    Received orphan drug designation from the U.S. FDA for ivaltinostat to treat hepatocellular carcinoma

  • 07

    Signed tech transfer agreement with Machaon Therapeutics for the right to develop ivaltinostat for fibrotic diseases

  • 07

    Established subsidiary, Machaon Therapuetics, to focus on developing therapeutics for fibrosis

  • 06

    Completed EU Phase 1 study of CG-549 (novel antibiotic with improved formulation) to treat MRSA infections

  • 06

    Granted a patent for a new drug candidate (ivaltinostat) for acute myelogenous leukemia in Australia

  • 04

    Signed a license-in contract for the PD-1 inhibitor, camrelizumab, with China's Jiangsu Hengrui Medicine Co., Ltd.

  • 03

    Completed Phase 2 study of ivaltinostat for treatment of pancreatic cancer

  • 03

    Granted a U.S. patent for a new drug candidate (ivaltinostat) for acute myeloid leukemia

  • 01

    Granted a patent for polmacoxib for arthritis / inflammatory diseases in Australia

2019
  • 11

    Established Crystal Bioscience, a new technology investment company

  • 11

    Granted a Korean patent for transdermal formulation of polmacoxib

  • 10

    Acquired license for manufacturing and sales of Acelex tablets by Korea's Ministry of Food and Drug Safety

  • 08

    Received orphan drug designation from the U.S. FDA for ivaltinostat to treat pancreatic cancer

  • 08

    Received the top award at the "ITS 2019 Innovative Technology Show’ from the Ministry of Small Medium Enterprise and Startups

  • 08

    Acquired EMA IND approval for Phase 1 study of CG-549 to treat MRSA infections

  • 08

    Granted a Korean patent for a new drug candidate (ivaltinostat) for acute myelogenous leukemia

  • 08

    Granted a U.S. patent for polmacoxib for arthritis / inflammatory diseases

  • 06

    Completed Korean Phase 1 study for polmacoxib + tramadol FDC

  • 06

    Acquired IND approval for Phase 1 study for polmacoxib + pregabalin FDC

  • 04

    Signed export agreement of polmacoxib with PharmArtis for expansion of commercialization into the Eurasian Economic Union (EAEU)

  • 03

    Acquired FDA IND approval for the Phase 1 study of CG-806 for acute myelogenous leukemia

  • 02

    Granted a patent for CG-806 for acute myelogenous leukemia in Turkey

  • 02

    Granted a patent for CG-806 for acute myelogenous leukemia in Russia

2018
  • 12

    Awarded as ‘Excellent Corporation R&D Center’ by the Ministry of Science and Information Communication Technology

  • 11

    Awarded as ’World Class Product of Korea’ (Acelex) by the Ministry of Trade, Industry and Energy

  • 11

    Signed export agreement of polmacoxib with PharmArtis for commercialization in Russia

  • 11

    Awarded as ‘Korea"s Innovative Pharmaceutical Company’ by President of Korea Health Industry Development Institute

  • 10

    Filed for patent for ivaltinostat - oral formulation

  • 09

    Received "Osong New Drug & Medical Expert" Grand Award

  • 09

    Signed export agreement of polmacoxib with APSEN for commercialization in Brazil

  • 09

    Granted a patent for CG-806 for acute myelogenous leukemia in Europe

  • 06

    Granted a patent for polmacoxib for arthritis and inflammatory diseases in Europe

  • 06

    Signed agreement with Aptose Biosciences (U.S.) for Aptose to acquire licensing rights to export CG-806 into China to treat hematological malignancies

  • 06

    Designated ivaltinostat as an "Developmental Orphan Drug" by Korea"s Ministry of Food and Drug Safety for pancreatic cancer

  • 06

    Renewed the designation as an Innovative Pharmaceutical Company by the Korean government

  • 03

    Acquired IND approval for Phase 1 study for polmacoxib + tramadol FDC from Ministry of Food and Drug Safety

  • 03

    Signed agreement with Daewoong Pharmaceutical for commercialization of Acelex in Korea

  • 01

    Received trademark rights of next-gen arthritis and anti-inflammatory drug ‘Acelex’ in 35 countries

2017
  • 11

    Granted a patent for CG-806 for acute myelogenous leukemia in China

  • 11

    Granted a patent for polmacoxib for arthritis and inflammatory diseases in Japan

  • 11

    Awarded “President’s Award” from “2017 Korea Technology Convention” by Ministry of Trade, Industry and Energy

  • 09

    Granted a patent for CG-806 for acute myelogenous leukemia in U.S.

  • 09

    Granted a Korean patent for polmacoxib + tramadol FDC to treat moderate to severe chronic pain

  • 03

    Received the 2016 Prime Minister's iR52 Jang Young-shil Award from KOITA, MBN, Ministry of Science and ICT

2016
  • 07

    Re-nominated as a “K-Brain Power” company by Korea's Ministry of Trade, Industry and Energy

  • 06

    Licensed out CG-806 to Aptose Biosciences, Inc. (U.S.)

  • 02

    Received “Korea New Drug Grand Award” by Korea Drug Research Association

  • 01

    Signed export agreement of Acelex with TR Pharm for commercialization in MENA and Turkey

2015
  • 12

    Received ‘Korea Innovative Pharmaceutical Company’ award from Korea"s Ministry of Health and Welfare

  • 12

    Acquired BTO Biopharmaceuticals (now known as CrystalLifeSciences Co., Ltd.)

  • 07

    Signed agreement with Dong-A ST Co., Ltd. for sales and marketing of Acelex

  • 03

    Received IND approval for Phase 1/2 clinical study for ivaltinostat to treat myelodysplastic syndrome (MDS)

  • 02

    Received NDA approval of Acelex (next-gen arthritis / anti-inflammatory drug) becoming the 22nd new drug approved in Korea and 1st from a Korean bioventure

  • 02

    Designated ivaltinostat as an "Developmental Orphan Drug" by Korea"s Ministry of Food and Drug Safety for MDS

2013
  • 10

    Received IND approval for Phase 1/2 clinical study for ivaltinostat to treat pancreatic ductal adenocarcinoma

  • 08

    Acquired controlling stake of Hwail Pharma Co., Ltd.

  • 06

    Completed Phase 1 clinical study of ivaltinostat

  • 01

    Reported U.S. Phase 2a clinical study results for CG-549 (antibiotic candidate) to treat MRSA

2012
  • 10

    Received IND approval for Phase 3 clinical study for Acelex

  • 06

    Designated as "Korea Innovative Pharmaceutical Company" by the Ministry of Health and Welfare

  • 05

    Completed Phase 2b clinical study of Acelex

  • 04

    Received IND approval from the FDA for Phase 2a clinical study for CG-549 to treat MRSA

  • 01

    Received investment from the "Global Biomedical New Growth Power Investment Fund" by the Seoul metropolitan government

2011
  • 11

    Awarded a grant from Korea's OncoVenture fund for the Global Oncology Drug Development program

  • 09

    Relocated HQ to Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeongi-do, Republic of Korea

  • 08

    Acquired NexioLab

  • 05

    Received IND approval from MFDS for Phase 1 MAD clinical study for ivaltinostat

  • 04

    Completed Phase 1 MAD clinical study in Europe for CG-549 to treat MRSA

  • 01

    Received IND approval from MFDS for Phase 2b clinical study for Acelex

2010’s - 2000’s
2010
  • 05

    Received IND approval from MFDS for Phase 1 SAD clinical study for ivaltinostat

  • 01

    Signed strategic alliance agreement for joint R&D program to develop novel antibiotics with AstraZeneca

2009
  • 10

    Received IND approval for Phase 1 clinical study in Europe for CG-549 to treat MRSA

2008
  • 05

    Received strategic investment of 30.6 Trillion KRW from Hanmi Pharmaceutical

  • 02

    Signed strategic alliance agreement with U.S.-based venture capital firm,
    ProQuest and established a joint venture, Palkion (U.S.)
    for anemia drug development

2006
  • 11

    Established U.S. subsidiary, CG Pharmaceuticals, Inc. in California

  • 05

    Signed licensing agreement with AmorePacific Corporation on developing anti-inflammatory drug candidates

  • 04

    Signed a strategic R&D agreement with Ginko (a SoftBank invested biotech in Japan) for targeted anticancer drugs

  • 03

    Signed a strategic research agreement with Daiichi-Sankyo Pharmaceutical (Japan) for targeted anticancer drugs

  • 02

    Signed a strategic research agreement with Carna Biosciences (Japan) for anti-inflammatory drugs

  • 01

    Listed on the KOSDAQ (ticker number: 083790)

2005
  • 10

    Signed strategic research agreement with Oncotherapy (Japan) for targeted anticancer drugs

  • 06

    Signed joint research agreement with Korea Research Institute of Chemical Technology for a targeted anticancer drug

2004
  • 05

    Published “Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125” in The EMBO Journal

2003
  • 09

    Published a Nature cover story on the “Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules

2002
  • 11

    Received the Minister Award for Best Venture Entrepreneur from the Ministry of Trade, Industry and Energy

  • 02

    Signed research agreement with KT&G for novel antibiotics

2001
  • 11

    Signed research agreement with Yuyu Pharma, Inc. for novel diabetic therapeutics

2000
  • 07

    Founded CrystalGenomics, Inc.